Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Liquidia Corporation Common Stock (LQDA)

Pharmaceutical Preparations

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

419 DAVIS DRIVE, SUITE 100
MORRISVILLE, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/26/2018

Market Cap

1,083,559,107

Shares Outstanding

75,810,000

Weighted SO

75,812,107

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

BMRN --.--%

PCVX --.--%

LEGN --.--%

TECH --.--%

UTHR --.--%

GERN --.--%

NRXP --.--%

AGEN --.--%

REPL --.--%

Beta

0.3210

Last Div

0.0000

Range

5.71-16.99

Chg

0.2800

Avg Vol

871074

Mkt Cap

1083559107

Exch

NASDAQ

Country

US

Phone

919 328 4400

DCF Diff

25.5700

DCF

-11.7400

Div Yield

0.0000

P/S

73.0161

EV Multiple

-10.1103

P/FV

17.1951

Div Yield %

0.0000

P/E

-9.6201

PEG

-0.8973

Payout

0.0000

Current Ratio

6.0801

Quick Ratio

5.7824

Cash Ratio

5.4952

DSO

79.9114

DIO

490.2011

Op Cycle

570.1125

DPO

390.2169

CCC

179.8956

Gross Margin

0.6381

Op Margin

-6.5583

Pretax Margin

-7.5546

Net Margin

-7.5546

Eff Tax Rate

0.0097

ROA

-0.6321

ROE

-1.8358

ROCE

-0.6355

NI/EBT

1.0000

EBT/EBIT

1.1519

EBIT/Rev

-6.5583

Debt Ratio

0.4776

D/E

1.3506

LT Debt/Cap

0.5710

Total Debt/Cap

0.5746

Int Coverage

-26.6863

CF/Debt

-0.8861

Equity Multi

2.8277

Rec Turnover

4.5676

Pay Turnover

0.9354

Inv Turnover

0.7446

FA Turnover

1.8885

Asset Turnover

0.0837

OCF/Share

-0.9821

FCF/Share

-1.1469

Cash/Share

1.7412

OCF/Sales

-5.0586

FCF/OCF

1.1678

CF Coverage

-0.8861

ST Coverage

-61.2816

CapEx Coverage

-5.9603

Div&CapEx Cov

-5.9603

P/BV

17.1951

P/B

17.1951

P/S

73.0161

P/E

-9.6201

P/FCF

-12.3602

P/OCF

-14.3667

P/CF

-14.3667

PEG

-0.8973

P/S

73.0161

EV Multiple

-10.1103

P/FV

17.1951

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 19, 06:30 Liquidia Corporation Announces Updates to Operations Leadership GlobeNewswire Inc. Jan 05, 06:45 Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD GlobeNewswire Inc. Jan 02, 06:45 Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 21, 12:00 B of A Securities Maintains Buy Rating for Liquidia: Here's What You Need To Know GlobeNewswire Inc. Dec 20, 16:56 U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent) GlobeNewswire Inc. Dec 20, 16:56 U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent) GlobeNewswire Inc. Nov 07, 06:30 Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update GlobeNewswire Inc. Oct 31, 06:30 Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

Revenue Product Segmentation